- Home
- KGEI vs DMAC Comparison
KGEI vs DMAC Comparison
Compare KGEI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- DMAC
- Stock Information
- Founded
- KGEI 2008
- DMAC 2000
- Country
- KGEI United States
- DMAC United States
- Employees
- KGEI N/A
- DMAC N/A
- Industry
- KGEI
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- DMAC Health Care
- Exchange
- KGEI Nasdaq
- DMAC Nasdaq
- Market Cap
- KGEI 269.7M
- DMAC 267.7M
- IPO Year
- KGEI N/A
- DMAC N/A
- Fundamental
- Price
- KGEI $8.32
- DMAC $6.51
- Analyst Decision
- KGEI Strong Buy
- DMAC Strong Buy
- Analyst Count
- KGEI 1
- DMAC 3
- Target Price
- KGEI $11.00
- DMAC $7.00
- AVG Volume (30 Days)
- KGEI 149.5K
- DMAC 81.8K
- Earning Date
- KGEI 11-12-2024
- DMAC 03-18-2025
- Dividend Yield
- KGEI N/A
- DMAC N/A
- EPS Growth
- KGEI 2.07
- DMAC N/A
- EPS
- KGEI 0.48
- DMAC N/A
- Revenue
- KGEI $54,654,000.00
- DMAC N/A
- Revenue This Year
- KGEI $15.83
- DMAC N/A
- Revenue Next Year
- KGEI $26.54
- DMAC N/A
- P/E Ratio
- KGEI $17.06
- DMAC N/A
- Revenue Growth
- KGEI 16.56
- DMAC N/A
- 52 Week Low
- KGEI $2.85
- DMAC $2.14
- 52 Week High
- KGEI $9.89
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- KGEI 58.87
- DMAC 62.22
- Support Level
- KGEI $8.22
- DMAC $5.75
- Resistance Level
- KGEI $9.89
- DMAC $6.82
- Average True Range (ATR)
- KGEI 0.66
- DMAC 0.30
- MACD
- KGEI -0.01
- DMAC 0.02
- Stochastic Oscillator
- KGEI 45.67
- DMAC 74.48
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.